Electronic Supplementary Material (ESI) for Catalysis Science & Technology. This journal is © The Royal Society of Chemistry 2017

### Electronic Supplementary Information

# Transformation of formaldehyde into functional sugars via multi-enzyme stepwise cascade catalysis

Jiangang Yang<sup>a</sup><sup>§</sup>, Shangshang Sun<sup>ba</sup><sup>§</sup>, Yan Men<sup>a</sup>, Yan Zeng<sup>a</sup>, Yueming Zhu<sup>a</sup>, Yuanxia Sun<sup>a</sup>\*, Yanhe Ma<sup>a</sup>

 <sup>a</sup> National Engineering Laboratory for Industrial Enzymes, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences,

Tianjin 300308, China.

E-mail: sun\_yx@tib.cas.cn

- <sup>b</sup> University of Chinese Academy of Sciences, Beijing, China
- § These authors contributed equally to this work.
- \* Corresponding author: E-mail: sun\_yx@tib.cas.cn; Tel.: +86 22 84861960; fax: +86 22 84861961.

#### **Experimental Section**

#### **Bacterial Strains, Plasmids and Materials**

Compounds FALD, GALD, DHA, ampicillin and isopropyl-β-Dthiogalactopyranoside (IPTG) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Strains, plasmids, and primers used in this study were shown in Table S1 and S2.

#### Vector construction

Full-length gene of FLS as reported in Siegel's study was synthesised by GeneScript (Nanjing, China). The *fsa* gene from *E. coli* was amplified using primer sets FSA-1(*NdeI*)/FSA-2(*Hind*III). The resulting fragment was inserted into plasmid pET-21a (+) at *NdeI* and *Hind*III sites to obtain pET21-FSA. Mutant FSA<sup>A129S</sup> was constructed with the aid of the QuikChange site-directed mutagenesis kit (Stratagene), the oligonucleotides listed in the Table S2 and with the plasmid pET21-FSA as template. DNA sequencing analysis confirmed the expected mutations in the gene sequence.

#### Recombinant proteins expression and purification

*E. coli* BL21(DE3) strains harboring expression plasmids were cultured at 37 °C in 1 L LB medium containing 100 mg/L ampicillin to an optical density  $OD_{600}$  of 0.6. 0.5 mM IPTG was added into the culture to induce protein expression and the temperature was adjusted to 16 °C to avoid inclusion body formation. After incubation for an additional 20 h, cells were harvested, washed twice and suspended in 50 mM triethanolamine (TEA) (pH 7.5) buffer. The suspension cells were then lysed by sonication and centrifuged at  $14,000 \times g$  and 4 °C for 10 min. Clear supernatant was collected and loaded onto a Ni<sup>2+</sup>-NTA-agarose column preequilibrated with binding buffer (50 mM TEA buffer, 300 mM NaCl, 20 mM imidazole, pH 7.5). The retained proteins were recovered with elution buffer (50 mM TEA buffer, 300 mM NaCl, 300 mM imidazole, pH 7.5). The eluted fraction containing purified protein was dialyzed and stored at -20 °C.

#### Enzyme activity assays.

FLS activity: The activity was assayed in a reaction mixture (200 µl) containing FLS (0.8 mg), 25 mM TEA buffer (pH 7.0), and 25 mM formaldehyde (FALD). After the conversion at 30°C for 30 min, the product was determined via high-performance liquid chromatography (HPLC) as described below. One unit of enzyme activity was defined as the enzyme amount catalyzing the formation of 1 µmol product per min.

FSA activity: The FSA activity was measured in a reaction mixture (200  $\mu$ l) containing FSA (0.1 mg), 25 mM FALD, 25 mM glycolaldehyde (GALD) and 25 mM TEA buffer (pH 7.0). The reaction mixture was incubated at 30°C for 10 min. The concentration of L-glyceraldehyde (**3a**) produced from FALD and GALD was determined via HPLC. One unit of enzyme activity was defined as the enzyme amount catalyzing the formation of 1  $\mu$ mol product per min.

FSA<sup>A129S</sup> activity for L-erythrulose (**4a**) synthesis: The activity of FSA<sup>A129S</sup> was determined in a reaction mixture (200  $\mu$ l) containing FSA<sup>A129S</sup> (0.1 mg), 25 mM FALD, 25 mM dihydroxyacetone (DHA) and 25 mM TEA buffer (pH 7.0). The reaction mixture was incubated at 30°C for 10 min. The concentration of **4a** produced

from FALD and DHA was determined via HPLC. One unit of enzyme activity was defined as the enzyme amount catalyzing the formation of 1 µmol product per min.

FSA<sup>A129S</sup> activity for L-sorbose (**6a**) synthesis: The activity of FSA<sup>A129S</sup> was determined in a reaction mixture (200  $\mu$ l) containing FSA<sup>A129S</sup> (0.1 mg), 25 mM **3a**, 25 mM (DHA) and 25 mM TEA buffer (pH 7.0). The reaction mixture was incubated at 30°C for 10 min. The concentration of **6a** produced from **3a** and DHA was determined via HPLC. One unit of enzyme activity was defined as the enzyme amount catalyzing the formation of 1  $\mu$ mol product per min.

#### In vitro cascade reaction

To synthesise C3 precursor **3a**, one-pot reaction mixture (200 µl) containing 50 mM TEA (pH 7.5), 25 mM FALD, FLS and FSA was carried out at 25 °C and 120 rpm for 12 h. To obtain **3a** in a preparative scale, the reaction medium (50 mL) containing 50 mM FALD, FLS (2 U), FSA (12 U) in 100 mM tris-ethanolamine (TEA) buffer pH 7.5 was carried out at 25 °C and 100 rmp for 36 h. Samples were treated with 10 % H<sub>2</sub>SO<sub>4</sub> and centrifuged at 22,000 rpm for 20 min. The supernatant was concentrated under reduced pressure and purified using semi-preparative HPLC to afford the desired product **3a**. Isolated yield: 26%. <sup>1</sup>H NMR and <sup>13</sup>C spectra were identical to those in previous study. <sup>[1]</sup> <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O)  $\delta$  4.96 (s, 1H), 3.76 (d, *J* = 1.5 Hz, 1H), 3.64 (s, 1H), 3.61 (d, *J* = 0.7 Hz, 1H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O)  $\delta$  89.77, 74.05, 61.96.

To synthesise **4a**, the reaction mixture (2 mL) containing 50 mM TEA (pH 7.5), 25 mM FALD, and FLS (20 mg, 0.1 U) was initially carried out at 25 °C and 120 rpm

for 12 h. Then, FSA<sup>A129S</sup> (1 mg, 0.64 U) and FALD (8 mM) were added into the reaction system, and it performed for another 12 h. Samples (100 µl) were captured very one hour, treated with 10 % H<sub>2</sub>SO<sub>4</sub>, centrifuged (22,000 rpm, 20 min) and analysed by HPLC. For a preparative scale, the reaction mixture (50 mL) containing 50 mM TEA (pH 7.5), 50 mM FALD, and FLS (2 U) was initially carried out at 25 °C and 120 rpm for 12 h. Then, FSA<sup>A129S</sup> (5 U) and FALD (8 mM) were added into the reaction system, and it performed for another 12 h. The supernatant was concentrated under reduced pressure and purified using semi-preparative HPLC to afford the desired product **4a**. Isolated yield: 66%.<sup>1</sup>H NMR and <sup>13</sup>C spectra were identical to those in previous study. <sup>[2]</sup> <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O)  $\delta$  4.62 (d, *J* = 19.4 Hz, 1H), 4.54 (d, *J* = 19.4 Hz, 1H), 4.47 (t, *J* = 4.1 Hz, 1H), 3.89 (d, *J* = 2.3 Hz, 1H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O)  $\delta$  212.30, 75.83, 65.80, 62.84.

To synthesise **6a**, one-pot reaction mixture (2 mL) containing 50 mM TEA (pH 7.5), 25 mM FALD, FLS (20 mg, 0.1 U) and FSA (2 mg, 0.32 U) was initially carried out at 25 °C and 120 rpm for 12 h. Then, FSA<sup>A129S</sup> (0.8 mg, 5 U) were added into the reaction system, and it performed for another 12 h. Samples (100 µl) were captured very one hour, treated with 10 % H<sub>2</sub>SO<sub>4</sub>, centrifuged (22,000 rpm, 20 min) and analyzed by HPLC. For a preparative scale, the reaction medium (50 mL) containing 50 mM FALD, FLS (2 U), FSA (15 U) in 100 mM tris-ethanolamine (TEA) buffer pH 7.5 was carried out at 25°C and 100 rmp for 36 h. Then, FSA<sup>A129S</sup> (5 U) were added into the reaction system, and it performed for another 12 h. The supernatant was concentrated under reduced pressure and purified using semi-preparative HPLC to

afford the desired product **6a**. Isolated yield: 43%.<sup>1</sup>H NMR and <sup>13</sup>C spectra were identical to those in previous study. <sup>[3]</sup> <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O)  $\delta$  3.79 – 3.74 (m, 1H), 3.73 (d, *J* = 5.0 Hz, 1H), 3.71 – 3.69 (m, 1H), 3.68 (s, 1H), 3.66 – 3.63 (m, 1H), 3.54 (d, *J* = 9.0 Hz, 1H), 3.52 (d, *J* = 6.5 Hz, 1H). <sup>13</sup>C NMR (101 MHz, D<sub>2</sub>O)  $\delta$  97.71, 73.83, 70.37, 69.40, 63.47, 61.76.

#### Whole-cell transformation

The recombinant *E. coli* strains were initially cultivated in 500 mL of LB medium to an  $OD_{600}$  of 0.6 and then induced with 1 mM IPTG for 20 h at 20°C and 120 rmp. Subsequently, the cells were harvested by centrifugation (8.000×g, 10 min, 4 °C), washed twice and suspended in TEA buffer (50 mM, pH 7.5). The reaction medium containing 30 g cdw l<sup>-1</sup> ( $OD_{600}$ =120) resting cells expressing FSA<sup>A129S</sup>, 2 M or 3 M substrates (FALD and DHA) were carried out at 30°C and 120 rmp for 4 hours.

For stepwise cascade whole-cell transformation, the cell catalyst overexpressing FSA (5 g cdw l<sup>-1</sup>), 200 mM FALD and 50 mM GALD were added together in the reaction mixture (2 mL). The reaction system was initially performed at 30 °C and 120 rpm for 4 hours. Then, cell catalyst overexpressing FSA<sup>A129S</sup> (5 g cdw l<sup>-1</sup>) and 180 mM DHA supplemented into the system and the reaction process continued for another 4 hours. Samples (100  $\mu$ l) were captured very 30 min, centrifuged (14,000 rpm, 20 min) and analyzed by HPLC.

#### **Analytical Methods**

Protein concentrations were determined by the Bradford method using bovine serum albumin as a standard. Compounds FALD, GALD, DHA, **3a**, **4a**, and **6a** were measured using HPLC system (Agilent 1100 series, Hewlett-Packard), equipped with a refractive index detector. The HPLC was fitted with a Bio-Rad Aminex HPX-87H column. The mobile phase consisted of 10 mM  $H_2SO_4$  at 0.5 mL min<sup>-1</sup> (55 °C).

Strains and plasmids	Genotype and properties	Source or reference
Strain		
<i>E. coli</i> DH5α	supE44 ΔlacU169 (φ80 lacZΔM15) hsdR17 recA	l Novagen
	endA1 gyrA96 thi-1 relA1	
E. coli BL21 (DE3)	F-ompT hsdSB (Rb - mB - ) gal (λ c I 857 ind1 Sam)	7 Novagen
	nin5 lacUV5 T7gene1) dcm (DE3)	
Plasmid		
pET21a(+)	Expression vector, $Ap^{R}$	Invitrogen
pETDuet	Expression vector, $Ap^{R}$	Invitrogen
pET-FLS	pET21a(+) derivative carrying gene FLS which was	s This study
	synthesized from GeneScript	
pET-FSA	pET21a(+) derivative carrying gene sequence of <i>fsa</i>	This study
pET-FSAA1298	pET21a(+) derivative carrying gene sequence o	f This study
	mutant FSA <sup>A129S</sup>	
pET-T7-FLS-T7-	pETDuet derivative carrying gene sequence of FLa	S This study
FSA <sup>A129S</sup>	and FSA <sup>A1298</sup>	

Table S1 Strains and plasmids used in this study.

Primer	Oligonucleotide sequence
FSA-1	GGAATTCCATATGcatcatcaccatcaccatGAACTGTATCTGGATACTTCAGAC
FSA-2	ACTCAAGCTTCTATTAAATCGACGTTCTGCCAAA
FSA <sup>A129S</sup> -1	TGCGGAATATGTTTCGCCTTACGTTAATCG
FSA <sup>A1298</sup> -2	CGATTAACGTAAGGCGAAACATATTCCGCA

Table S2 Primers used in this study.

Figure S1 The effect of concentration ratio of FALD to GALD on conversion rate in vitro.



Figure S2 SDS-PAGE analysis of purified FLS, FSA, and FSA<sup>A129S</sup>. M: Marker; 1:

Purified FLS; 2: Purified FSA; 3: Purified FSA<sup>A129S</sup>.



Figure S3 NMR analysis of **3a**, **4a**, and **6a**.









## (3) $^{1}$ H and $^{13}$ C spectra of **6a**



Fig. S4 Whole-cell transformation of FALD to synthesise **4a** using recombinant strain expressing both of FLS and FSA<sup>A129S</sup>. (A) The standard of **4a**; (B) Whole-cell transformation of FALD to synthesise **4a**.



Reference

- [1] X. Garrabou, J.A. Castillo, C. Guérard-Hélaine, T. Parella, J. Joglar, M. Lemaire,
  P. Clapés, *Angew Chem Int Ed*, 2009, *121*, 5629–5633.
- [2] J. A. Castillo, C.Guérard-Hélaine, M. Gutiérrez, X. Garrabou, M. Sancelme, M. Schürmann, T. Inoue, V. Hélaine, F. Charmantray, T. Gefflaut, L. Hecquet, J. Joglar, P. Clapés, G. A. Sprenger, M. Lemaire, *Adv. Synth. Catal*, **2010**, *352*, 1039–1046.
- [3] A. Blaskó, C.A. Bunton, E. Moroga, S. Bunel, C. Ibarra. Carbohydr. Res, 1995, 278, 315.